Could a Single Oligonucleotide Medication Treat Multiple Different Diseases?
Our relatively new field is swiftly growing, and another exciting novel therapeutic RNA modality is now gaining traction. tRNA is vital in protein synthesis and by engineering tRNA molecules...
Chemical and Nanotechnology-based Approaches to Build Next-gen Oligonucleotide Therapeutics
Join Aurélie Lacroix, PhD and Leonora Abdullahu, PhD, the 2021/2022 OTS Trainee Reps, as they share about their research and career paths. Speaker: Aurélie Lacroix, PhD, Senior Scientist / MSCA fellow, Sixfold Bioscience Bio ...
Support for Ukrainian Scientists
The OTS joins other scientific organizations in seeking to help Ukrainian scientists. Specifically, we invite Ukrainian students, scientists, and industry professionals with interests in the field of nucleic acids and oligonucleotide therapeutics to post their contact information and CVs on the OTS website. We ...
Antisense Oligonucleotide-based Therapies for Inherited Retinal Diseases: From Mutation to Clinical Trial
Speaker: Alex Garanto, PhD Date: March 10, 2022 Time: 11-12 EST Description: The eye is at the forefront of therapeutic development for its unique properties. Local delivery of ASOs to the retina has shown to be well tolerated and safe. During this webinar, Prof. ...
A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy
 Typically, a single copy of a gene is enough to support normal growth and development but in a small subset of genes, the loss of one copy can cause serious diseases that are often difficult to treat. One of these conditions, Dravet Syndrome, has no ...
Meet Your 2022 OTS Trainee Reps
Speaker: Chantal Ferguson, MD, PhD Candidate and Hassan Fakih, PhD Date: February 24, 2022 Time: 11-12 EST Description: The OTS values and encourages the contribution of trainees to the society. The trainee representative to the Board of Directors position was created to give trainees ...
A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS
 Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those who must live with it. They will experience loss of motor control of the arms ...
A Perspective From Industry – A Conversation With Richard S. Geary, Ph.D. Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals
Speaker: Richard S. Geary, Ph.D. Date: February 10, 2022 Time: 11-12 EST Description: The OTS Webinar series is pleased to feature Dr. Richard Geary, the current President Elect, and the Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals. For part of the webinar ...
Interview with Punit Seth, PhD
Punit Seth, PhD SVP Research, Alnylam Pharmaceuticals How did you become interested in the field of oligonucleotides? It was serendipity. I was hired 21 years back as an organic chemist at Ibis Therapeutics, a division of Isis Pharmaceuticals, to target structured RNA with ...
Does CRISPR Gene Editing Increase the Risk of Developing Cancer?
 CRISPR is a useful tool in a wide array of applications, and one of the most headline-grabbing is its potential in gene editing. As with any new technology or medication, there are inherent risks that must be discovered and mitigated. This is especially true in ...
